Key result
Novel HiBiT-tagged HBoV1 screening identifies ivermectin as a potent antiviral drug.
Why the study?
A lack of sensitive cell lines and efficient animal models hinders research on HBoV1, including the development of antiviral drugs or vaccines.
Effect estimate: EC50 = 2.27 μM
The HBoV1-HiBiT NS1 reporter strain serves as a viable platform for screening antiviral drugs against HBoV1, identifying ivermectin as a potent inhibitor.
Provides a screening platform for HBoV1 antivirals; leaves open ivermectin's clinical utility pending human studies.
Human bocavirus 1 (HBoV1; family: Parvoviridae ) causes a wide spectrum of respiratory diseases in children and gastroenteritis in adults. A lack of sensitive cell lines and efficient animal models hinders research on HBoV, including the development of anti-HBoV drugs or vaccines. Although the construction of a wild-type HBoV1 infectious clone has been reported, generating HBoV1 infectious clone carrying foreign reporter genes with suitable insertion sites in its genome while retaining replicative ability remains challenging. Here, HBoV1 infectious clones harboring the 11-amino-acid HiBiT tag at five distinct insertion sites were constructed and evaluated. Only the recombinant HBoV1 carrying the HiBiT tag in the N-terminus of the NS1 protein (HBoV1-HiBiT NS1 ) displayed comparable characteristics to wild-type HBoV1 as determined via the analysis of viral DNA copy number, NanoLuc activity, viral protein expression, and the formation of replication intermediates. Notably, the replication kinetics of HBoV1-HiBiT NS1 could be examined by monitoring NanoLuc activity, which was noted to be correlated with the viral DNA level. Additionally, we successfully applied HiBiT-tagged HBoV1 for the evaluation of antiviral drug activity and identified ivermectin (EC50 = 2.27 μM) as a potent anti-HBoV1 replication drug. Overall, our study demonstrated that the HBoV1-HiBiT NS1 reporter can serve as a convenient platform for screening candidate drugs targeting HBoV1 replication and may also be useful for investigating the life cycle of the virus. • The recombinant HBoV1 carrying HiBiT tag in the N-terminus of the NS1 protein displayed comparable characteristics to HBoV1. • The replication kinetics of HBoV1-HiBiT NS1 could be examined by monitoring NanoLuc activity. • The HiBiT-tagged HBoV1 infectious clone could be applied for the evaluation of antiviral drug activity.
No takes yet. Share an insight, caveat, or question.
Tang et al. (2025) studied Human bocavirus 1 (HBoV1) infection. HBoV1-HiBiT NS1 reporter and Ivermectin vs. Wild-type HBoV1 was evaluated on Viral replication kinetics and antiviral drug activity (EC50 = 2.27 μM). A recombinant HBoV1 carrying a HiBiT tag in the NS1 protein displayed comparable characteristics to wild-type virus and identified ivermectin (EC50 = 2.27 μM) as a potent anti-HBoV1 drug.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: